E.07. Pharmacology-based nomenclature: ajoint ECNP, CINP, ACNP and AsCNP Task Force S151 [3] Phillips KA, Stein DJ, Rauch SL, Hollander E, Fallon BA, Barsky A, Fineberg N, Mataix-Cols D, Ferr˜ ao YA, Saxena S, Wilhelm S, Kelly MM, Clark LA, Pinto A, Bienvenu OJ, Farrow J, Leckman J. Should an obsessive–compulsive spectrum grouping of disorders be included in DSM-V? Depression and Anxiety, 27: 528–555, 2010. Disclosure statement: Dan Stein has received research grants and/or consultancy honoraria from Abbott, AMBRF, Astrazeneca, Biocodex, Eli- Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson, Lund- beck, National Responsible Gambling Foundation, Novartis, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, Sun, Takeda, Tikvah, and Wyeth. E.06.02 Evidence-based treatment for obsessive– compulsive and related disorders: an update N. Fineberg 1° , A. Brown 2 , S. Reghunandanan 3 , I. Pampaloni 4 1 Hertfordshire Partnership NHS University Foundation Trust and University of Hertfordshire, Hertfordshire, United Kingdom; 2 West London Mental Health Trust, London, United Kingdom; 3 Hertfordshire Partnership NHS University Foundation Trust and University of Hertfordshire, Welwyn Garden City, United Kingdom; 4 South West London and St George’s NHS Trust, Richmond Home Treatment Team, London, United Kingdom There is evidence of overlap and differentiation in the treatment response across the obsessive–compulsive and related disorders (OCRDs). Serotonin-reuptake inhibitor (SRI) and cognitive be- haviour therapy (CBT) with exposure and response prevention typically effect improvement in symptoms, disability and quality of life in obsessive–compulsive disorder (OCD) and body dys- morphic disorder. Ongoing SRI protects against relapse in OCD treatment-responders. Trichotillomania, in contrast, responds to CBT with habit reversal therapy and appears relatively SRI- unresponsive; preliminary data from randomized controlled trials suggest monotherapy with olanzapine (antipsychotic) and n-acetyl cysteine (amino acid) may be effective. Certain OCD symptoms have been associated with a poorer initial treatment-response, including hoarding behaviour and sleep-cycle disturbance. Ran- domised trials in SRI-resistant OCD provide some evidence of effectiveness for either adjunctive low-dose antipsychotic or el- evated selective SRI (SSRI) dosage. Combining CBT with SRI also appears effective in SRI-non-responders, and in a recent OCD study this strategy outperformed adjunctive risperidone [1]. However, a substantial proportion of patients with OCRD fail to achieve an acceptable level of symptomatic response and remain functionally disabled. Studies of novel pharmacothera- pies, including compounds acting on dopamine, glutamate and opiate receptors as well as antiepileptic agents, are producing evidence of potential efficacy in reducing obsessive–compulsive symptoms [2]. Modification of CBT with cognitive remediation therapy may also yield benefit. Recent small studies of repetitive transcranial magnetic stimulation (TMS), including deep TMS, show promise for OCD. Deep brain stimulation, which is under ongoing evaluation, and ablative neurosurgery are reserved for the most severely incapacitating, refractory OCD [3]. References [1] Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Ma- her MJ, McLean CP, Bender J Jr, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R. 2013. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive– compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 70(11):1190−9. [2] Fineberg NA, Brown A, Reghunandanan S, Pampaloni I. 2012. Evidence-based pharmacotherapy of obsessive–compulsive disorder. Int J Neuropsychopharmacol. 15(8):1173−91. [3] Fineberg NA, Reghunandanan S, Brown A, Pampaloni I. 2013. Pharmacotherapy of obsessive–compulsive disorder: Evidence-based treatment and beyond. Aust N Z J Psychiatry. 47(2):121−41. Disclosure statement: Consultancy: Dr Fineberg has consulted for Lund- beck, Glaxo-Smith Kline, Transcept, Novartis and Servier. Research sup- port: Dr Fineberg has received research support from Lundbeck, Glaxo- SmithKline, ECNP, Servier, UK MRC, UK NIHR, Wellcome Foundation. Honoraria for lectures: Dr Fineberg has received honoraria for lectures at scientific meetings from Lundbeck, Servier, Bristol Myers Squibb. Financial support to attend scientific meetings: Dr Fineberg has received financial support to attend scientific meetings from Lundbeck, Servier, Novartis, Bristol Myers Squibb, International College of OC Spectrum Disorders, International Society for Addiction, ECNP, BAP, WHO. E.07. Pharmacology-based nomenclature: ajoint ECNP, CINP, ACNP and AsCNP Task Force E.07.01 Pharmacology-based nomenclature - Introducing the concept and the template J. Zohar 1° 1 Chaim Sheba Medical Center, Department of Psychiatry, Tel Hashomer, Israel Objective: Current psychopharmacological nomenclature remains wedded to earlier period of scientific understanding, failing to reflect contemporary developments and knowledge, does not help clinicians to select the best medication for a given patient, and tending to confuse patients as they are being given a drug with a different name compared to their identified diagnosis (e.g. “Antipsychotic” for depression). A five-axis pharmacology based nomenclature template as a potential system which refresh current nomenclature by using contemporary scientific concepts of Neurospsychopharmacology will be presented. Methods: Four major colleges of Neuropsychopharmacology (ECNP, ACNP, Asian CNP, and CINP) proposed a new template comprising a multi-axial pharmacologically-driven nomenclature. The template comprises of five axes: 1 − class and Relevant mech- anism; 2 − sub-class; 3 − neurobiological activity; 4 − Efficacy (including major side effects); and 5 − Indications (FDA or EMA approved, or as stated). Several surveys in four different continents were conducted. Results: A significant proportion of the participants in the surveys were in favour of the proposed system, a similar number wanting to consider the idea further, and only a small proportion were against it. Conclusion: The results of the surveys suggest that clinicians found the available nomenclature system dissatisfactory and at times even confusing for them and the patients. In the session examples of using the multi axial system in key medications will be presented. Including dopamine receptor an- tagonist, GABA-and aminergic medications, ion channel blockers, reuptake inhibitors and enzyme inhibitor will be presented and discussed by the panel. Disclosure statement: Joseph Zohar has received grant/research support from Lundbeck, Servier and Pfizer, has served as a consultant or on advisory boards for Servier, Pfizer, Abbott, Lilly, Actelion, AstraZeneca and Roche, and has served on speakers’ bureaus for Lundbeck, Roch, Lilly, Servier, Pfizer and Abbott. E.07.03 From mood stabilisers to channel blockers G.M. Goodwin 1° 1 University of Oxford, Department of Psychiatry, Headington Oxford, United Kingdom The term mood stabilizer is in common use, even though it is both unofficial and anyway imprecisely describes what such medicines